

(43) International Publication Date
7 March 2013 (07.03.2013)(10) International Publication Number
WO 2013/029548 A1

(51) International Patent Classification:

C07D 215/56 (2006.01) A61K 31/47 (2006.01)
C07D 471/04 (2006.01) A61K 31/435 (2006.01)

(21) International Application Number:

PCT/CN2012/080753

(22) International Filing Date:

30 August 2012 (30.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2011/001477

31 August 2011 (31.08.2011)

CN

PCT/CN2012/001044 6 August 2012 (06.08.2012)

CN

(71) Applicant (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ABUDUSAIMI, Mamuti** [CN/CN]; c/o Otsuka Shanghai Research Institute, 3F, No. 1058 Halei Road, Pudong New District, Shanghai 201203 (CN). **YE, Fangguo** [CN/CN]; c/o Otsuka Shanghai Research Institute, 3F, No. 1058 Halei Road, Pudong New District, Shanghai 201203 (CN). **SUN, Jiangqin** [CN/CN]; c/o Otsuka Shanghai Research Institute, 3F, No. 1058 Halei Road, Pudong New District, Shanghai 201203 (CN). **MIYAMOTO, Hisashi** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 10F Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **CHENG, Jay-Fei** [US/CN]; c/o Otsuka Shanghai Research Institute, 3F, No. 1058 Halei Road,

Pudong New District, Shanghai 201203 (CN). **OKA, Daisuke** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 10F Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).

(74) Agent: **CHINA PATENT AGENT (HK)LTD.**; 22/F., Great Eagle Center, 23 Harbour Road, Wanchai, Hong Kong (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: QUINOLONE COMPOUND



(57) Abstract: The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R¹ is (1) cyclopropyl optionally substituted by to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R² is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R³ is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against *Clostridium difficile* and is useful for the prevention or treatment of intestinal infection such as *Clostridium difficile*-associated diarrhea.